| Literature DB >> 27106543 |
Morton Scheinberg1,2, Flavio Fernando Nogueira de Melo3, Adrian Nogueira Bueno4, Carolyne Mendes Costa5, Maria Lucia Alvares de Azevedo Bahr5, Enio Ribeiro Reis5.
Abstract
The objective of the study was to evaluate prospectively real-life experience on the effect of belimumab on patients with active systemic lupus erythematosus (SLE). Forty-eight patients with active SLE were evaluated after 1 year of continuous treatment. Thirty-eight patients were still on treatment at the end of 1 year, and it was possible to observe significant clinical improvement in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score with a decrease from 12 ± 3.0 to 2.5 ± 2.5, also a decrease on the daily steroid dose from 30 ± 12.5 to 7.5 ± 5.0 mg and partial improvement on serology. Belimumab treatment is associated with real benefit in the majority of patients that maintain active disease in spite of continuing on standard of care.Entities:
Keywords: Rheumatic diseases; SLE
Mesh：
Substances：
Year: 2016 PMID： 27106543 DOI： 10.1007/s10067-016-3268-z
Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980